Evidence map›Paper›PMID 36619163›Full record

ArticleFrontiers in molecular biosciences2022

The effect of membrane thickness on the membrane permeabilizing activity of the cyclic lipopeptide tolaasin II.

Jessica Steigenberger, Catherine Mergen, Vic De Roo, Niels Geudens, José C Martins, Heiko Heerklotz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Does regulation hold the key to optimizing lipopeptide production inFrontiers in bioengineering and biotechnology · 2024
    Review
  5. Article
  6. Article
  7. Exopolysaccharides fromOpen life sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Jessica SteigenbergerDepartment of Pharmaceutics, Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg, Germany.
Catherine MergenDepartment of Pharmaceutics, Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg, Germany.
Vic De RooNMR and Structure Analysis Research Group, Department of Organic and Macromolecular Chemistry, Ghent University, Ghent, Belgium.
Niels GeudensNMR and Structure Analysis Research Group, Department of Organic and Macromolecular Chemistry, Ghent University, Ghent, Belgium.
José C MartinsNMR and Structure Analysis Research Group, Department of Organic and Macromolecular Chemistry, Ghent University, Ghent, Belgium.
Heiko HeerklotzDepartment of Pharmaceutics, Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg, Germany.
Ghent University · BEUniversity of Freiburg · DEUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tolaasin II is an amphiphilic, membrane-active, cyclic lipopeptide produced by

Indexed as

cyclic lipopeptidesequi-activity analysismembrane stabilitymembrane thicknesspacking mismatchtolaasin II

Identifiers

PMID36619163
PMCPMC9817028
OpenAlexW4312117461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.